Abstract
Kredex ® (carvedilol) is a new beta-blocker with demonstrated efficacy in the treatment of congestive heart failure. We report the case of a 69-years-old man who presented with diffuse interstitial lung disease and pleural effusion and who had been taking carvedilol for one year. The patient's condition improved as soon as this treatment was stopped, without any additional treatment. The evolution of the radiological and functional signs and elimination of other possible causes of pneumonitis left us with the probable diagnosis of carvedilol-induced hypersensitivity pneumonitis. To our knowledge, this is the first reported case of carvedilol-induced hypersensitivity pneumonitis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Revue française d'allergologie et d'immunologie clinique
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
